A tripeptide three letters short of the Epithalon family. Claimed to wake up your chondrocytes.
What: Ala-Glu-Asp (AED), ~333 Da, developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology as the putative cartilage bioregulator. The tripeptide sibling of Epithalon (AEDG), Cardiogen (AEDR), Cortagen (AEDP), and Bronchogen (AEDL) — same acidic core, no C-terminal residue.
Does: Claimed to enter chondrocytes, reach chromatin, and drive transcription of collagen II, aggrecan, and MMP-regulatory genes. Cell-culture work shows increased chondrocyte proliferation in young and aged rat cartilage.
Evidence: Preclinical only. Publications concentrated in a single Khavinson-program lineage. No randomized controlled human trials. Neither ACR, EULAR, OARSI, nor AAOS mentions AED in any guideline.
Used by: Longevity hobbyists in Khavinson-style cycles for joint support. Not recognized in mainstream osteoarthritis management.
Bottom line: Preclinical signal, absent from every rheumatology guideline.
Cartalax is a synthetic short peptide within the Khavinson bioregulator program. Its sequence is Ala-Glu-Asp (AED), a tripeptide with an approximate molecular weight of 333 daltons. It shares the "Ala-Glu-Asp" acidic core with several Khavinson tetrapeptide siblings (Epithalon AEDG, Cortagen AEDP, Bronchogen AEDL, Cardiogen AEDR) — Cartalax is the shorter, three-residue version lacking the C-terminal residue. It is sometimes listed under the alias "AC-4." The two acidic residues (Glu, Asp) plus the small hydrophobic Ala give the tripeptide a net-anionic character under most buffer conditions, which the Khavinson framework interprets as favoring interaction with DNA-major-groove arginine-rich regions and with histone-linker basic patches.
Within the Khavinson framework, Cartalax is described as the putative short-peptide active fragment recovered from cartilage-tissue polypeptide fractions. The parent complex in earlier Russian work was derived from cartilage and joint-tissue extracts. As with other Khavinson bioregulators, Cartalax is presented as a chemically defined synthetic replacement for the crude tissue extract — solid-phase-synthesized, purified, and available as lyophilized research peptide or oral-capsule dietary supplement.
The commercial form is typically distributed as an oral capsule within the Khavinson Revilab / NPCRiZ dietary-supplement line and as lyophilized research peptide (20 mg vials are common) for subcutaneous or intramuscular research use. Neither form is registered as a pharmaceutical in any jurisdiction. In Russia it is sold as a BAD (biologically active additive); outside Russia it is research-only.
In the Western optimization community, Cartalax is used by a small niche of longevity-focused users within Khavinson-protocol stacks interested in cartilage- and connective-tissue-directed peptides. It is not a drug used or recognized in evidence-based rheumatology or orthopedics. Guideline-directed osteoarthritis management — weight optimization, exercise / physical therapy, topical and oral NSAIDs, intra-articular corticosteroids or hyaluronic acid, DMOADs in trial, and joint replacement in advanced disease — does not include Cartalax.
The Khavinson framework proposes that short bioregulator peptides act as sequence-specific DNA-binding molecules or intracellular epigenetic modulators that can enter cells and reach nuclear chromatin. Cartalax's mechanism is described within this framework. Independent structural validation is limited.
Limitation: as with other Khavinson bioregulators, mechanism is primarily a hypothesis developed within one research program and has not been independently validated at the level of structural biology, ChIP-seq, or prospective gene-target mapping.
Cartalax's published literature is concentrated in Russian-language and English-language Springer-indexed Khavinson-program publications. Evidence is preclinical — cell-culture and small-animal data — with no randomized controlled human trials.
Cartalax's evidence base is preclinical, dominated by a single research program, and not independently replicated by Western rheumatology or orthopedic research. No randomized controlled human trials exist. Mainstream joint-disease management does not recognize Cartalax. Substituting Cartalax for evidence-based osteoarthritis care is inappropriate. Claims that Cartalax "treats" osteoarthritis or "regrows cartilage" in humans are unsupported.
Synthetic Cartalax (AED) has not been evaluated in published randomized controlled human trials. Accessible human-use information consists of:
Where the Cartalax program intersects with the broader osteoarthritis and connective-tissue research literature — collagen biology, proteoglycan metabolism, MMP regulation, and chondrocyte survival pathways — there are thousands of peer-reviewed publications describing each of these biological axes in detail, but virtually none of them reference AED. The Khavinson-program contribution sits outside the mainstream rheumatology research community; there is essentially no citation crosstalk between the two. For a user evaluating Cartalax, the practical implication is that the compound's narrative and biological framing come almost entirely from a single lab group's papers, and independent verification at the level of cartilage-volume imaging, synovial-fluid biomarkers, histological scoring, or patient-reported outcome measures has not occurred.
Understanding where Cartalax fits — or does not fit — relative to current osteoarthritis management is important context for anyone considering it. OARSI 2019 and ACR 2019/2020 guidelines structure osteoarthritis treatment around a tiered model: foundational non-pharmacological management (exercise, weight management, education, patellofemoral offloading), then topical and oral NSAIDs, then intra-articular injections (corticosteroids, hyaluronic acid where indicated), then surgical options (arthroscopic where narrowly indicated, joint replacement in advanced disease). Every element of that model has RCT-level or meta-analytic support. Cartalax is not referenced in any of those guidelines, meta-analyses, or Cochrane reviews.
Within the pipeline of "disease-modifying osteoarthritis drugs" (DMOADs) — a research priority for two decades — compounds such as sprifermin (recombinant FGF-18), cindunistat, and lorecivivint have advanced through Phase 2/3 with MRI-based cartilage-volume endpoints. These programs sit in a completely separate research tradition from Cartalax and have orders-of-magnitude more evidence. When a community-level user considers "a peptide for cartilage," the scientific baseline comparison is with these clinical-development programs and standard-of-care management, not a Khavinson cross-referential claim.
This is not a rejection of Cartalax in principle — a research compound with honestly described preclinical data is valid research material. It is a request for calibrated expectations: users should not conflate "a short peptide with some preclinical activity in chondrocyte culture" with "a cartilage-regeneration therapy." The former is a mechanistic tool; the latter does not exist in any FDA-approved form. Continuing guideline-directed care while optionally layering a research compound on top is a categorically different posture from substituting Cartalax for osteoarthritis management, and the former is the only defensible framing.
No clinical-trial-derived human dose exists. The doses below summarize the Khavinson protocol framework and community practice. Not FDA-approved prescribing; not a rheumatology therapy.
| Form | Typical Dose | Frequency | Cycle / Notes |
|---|---|---|---|
| Oral capsule (Khavinson BAD — Revilab / NPCRiZ) | 200–400 μg | 1–2× daily | Microdose oral capsule product. 10–20 day course, 2–3 courses per year per protocol. |
| Oral lyophilized research peptide | 5–10 mg | Once daily | Community-level use of injectable-grade peptide orally/sublingually. Order(s)-of-magnitude higher than the BAD capsule; bioavailability poorly characterized. |
| Subcutaneous / IM injection | 100–200 μg | Once daily | Community injectable protocols, 10–20 day courses. |
| Course length | 10–20 days | — | Standard Khavinson bioregulator cycle. |
| Cycle frequency | 2–3 courses per year | — | Seasonal or elective timing. |
Large dosage gap between the Khavinson BAD microdose and the community research-peptide oral dose, without a validated human PK study. Community dosing is not clinically validated. Self-administration of research peptides for joint conditions is not a substitute for evidence-based rheumatology / orthopedic care. Consult a licensed clinician.
Research-peptide Cartalax is supplied lyophilized, typically in 10 mg or 20 mg vials. Oral BAD capsules are pre-formulated.
| Vial | BAC Water | Concentration | 100 μg Dose | 200 μg Dose |
|---|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL (5,000 μg/mL) | 2 units (0.02 mL) | 4 units (0.04 mL) |
| 10 mg | 5 mL | 2 mg/mL (2,000 μg/mL) | 5 units (0.05 mL) | 10 units (0.10 mL) |
| 20 mg | 2 mL | 10 mg/mL (10,000 μg/mL) | 1 unit (0.01 mL) | 2 units (0.02 mL) |
| 20 mg | 5 mL | 4 mg/mL (4,000 μg/mL) | 2.5 units (0.025 mL) | 5 units (0.05 mL) |
BPC-157 has preclinical data for tendon, ligament, and joint-tissue healing through angiogenesis and growth-factor modulation. Community protocols often pair BPC-157 with Cartalax during active joint rehabilitation. Not a clinically validated combination.
Cell-migration and connective-tissue-remodeling peptide, frequently stacked with BPC-157 and Cartalax in "joint/tendon recovery" community protocols. Preclinical mechanism overlap; clinical evidence sparse.
GHK-Cu has broader connective-tissue regeneration data, including cartilage-associated ECM synthesis in preclinical models. Mechanistically complementary framing with Cartalax within connective-tissue protocols.
Commonly included in the broader Khavinson longevity stack alongside tissue-specific peptides such as Cartalax.
Collagen peptides (10 g/day), vitamin C, vitamin D sufficiency, omega-3, and resistance training around affected joints are the highest-leverage adjuncts in osteoarthritis management — substantially more validated than any Khavinson peptide.
Cartalax is not approved by the U.S. FDA for any indication and has not been the subject of an IND or NDA filing. It is not approved by the European Medicines Agency.
In Russia, Cartalax is sold as a "biologically active additive" (BAD — dietary supplement) through Khavinson-affiliated distributors (NPCRiZ, Revilab). It is not a registered pharmaceutical.
Cartalax is not on the FDA Category 2 Bulk Drug Substances list, and it is not among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 2026 Category 2 reclassification announcement.
Cartalax is not specifically named on the WADA Prohibited List. Athletes should consult their sport-specific federation.
No rheumatology or orthopedic specialty society (ACR, EULAR, OARSI, AAOS) recognizes Cartalax as a therapeutic. Standard osteoarthritis management remains the standard of care.
Cartalax is not approved for human use in the United States. The oral BAD form is distributed internationally through Khavinson-affiliated channels; the injectable lyophilized peptide is available through research-chemical suppliers for laboratory research use only. Personal-use import to the U.S. occupies a legal gray zone; bulk import is enforced against.
No U.S. compounding pharmacy can legally compound Cartalax — it has no FDA-approved reference product and is not on the Category 1 bulk substance list. Purity verification via third-party HPLC + MS COA is the practical quality floor.
Cartalax is not among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 2026 Category 2 reclassification announcement. Absent formal FDA development, it will remain unavailable through legitimate U.S. clinical channels.
Access and availability information as of April 2026. Kalios does not sell compounds.
People researching Cartalax usually also check these Khavinson siblings:
Khavinson tripeptide (Lys-Glu-Asp). Vascular-endothelium-oriented bioregulator.
Khavinson tripeptide (Glu-Asp-Arg). Neuroprotective short-peptide bioregulator.
Khavinson tetrapeptide (Lys-Glu-Asp-Ala). Liver-oriented short peptide bioregulator.
Complex thymic extract peptide. Immune restoration and longevity-oriented bioregulator.
Khavinson tetrapeptide (Ala-Glu-Asp-Pro). Cerebral cortex-oriented bioregulator.
Last updated: April 2026 | Profile authored by Kalios Peptides research team